NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

1. A clinical decision framework for redox-adapted, EMT-high cancers: From ferroptosis resistance to precision therapeutic stratification.Redox biology · 2026
   Review
2. [Predictive Value of miRNAs Markers for Advanced Lung Squamous Cell Carcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
   Article
3. ATP-Binding Cassette Subfamily G Member 2 in Acute Myeloid Leukemia: A New Molecular Target?Biomedicines · 2024
   Review
4. MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.Frontiers in pharmacology · 2024
   Review
5. Nrf2 in human cancers: biological significance and therapeutic potential.American journal of cancer research · 2024
   Review
6. Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer.Biomedicines · 2022
   Article
7. The molecular biology and therapeutic potential of Nrf2 in leukemia.Cancer cell international · 2022
   Review
8. MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter:Acta pharmaceutica Sinica. B · 2022
   Article
9. Role of NRF2 in Ovarian Cancer.Antioxidants (Basel, Switzerland) · 2022
   Review
10. NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.Cancers · 2022
    Review
11. hsa-miR-206b Involves in the Development of Papillary Thyroid Carcinoma via Targeting LMX1B.BioMed research international · 2022
    Article
12. Multidrug efflux transporter ABCG2: expression and regulation.Cellular and molecular life sciences : CMLS · 2021
    Review
13. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance.Archives of pharmacal research · 2021
    Review
14. Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.Antioxidants (Basel, Switzerland) · 2021
    Review
15. Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.Cell death & disease · 2020
    Review
16. miR-206 inhibits liver cancer stem cell expansion by regulating EGFR expression.Cell cycle (Georgetown, Tex.) · 2020
    Article
17. Transcription factor-mediated regulation of the BCRP/Expert opinion on drug metabolism & toxicology · 2020
    Review
18. Retracted Article: MiR-206 reduced the malignancy of hepatocellular carcinoma cellsRSC advances · 2019
    Article
19. Potential Applications of NRF2 Inhibitors in Cancer Therapy.Oxidative medicine and cellular longevity · 2019
    Review
20. MicroRNA profiling associated with muscle growth in modern broilers compared to an unselected chicken breed.BMC genomics · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as